Arcus Biosciences (RCUS) Gains from Investment Securities (2016 - 2026)

Arcus Biosciences' Gains from Investment Securities history runs 11 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities changed N/A year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at -$2.0 million (down 116.67% YoY), while the FY2025 annual figure was -$5.0 million, down 171.43% from the prior year.
• Gains from Investment Securities was $3.0 million for Q1 2026 at Arcus Biosciences, up from -$5.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $14.0 million in Q4 2023 to a low of -$10.0 million in Q2 2022.
• Historically, Gains from Investment Securities has averaged $1.3 million across 5 years, with a median of $3.0 million in 2026.
• Biggest YoY gain for Gains from Investment Securities was 11211.11% in 2022; the steepest drop was 2350.98% in 2022.
• A 5-year view of Gains from Investment Securities shows it stood at -$6.0 million in 2022, then surged by 333.33% to $14.0 million in 2023, then slumped by 64.29% to $5.0 million in 2024, then tumbled by 200.0% to -$5.0 million in 2025, then surged by 160.0% to $3.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $3.0 million (Q1 2026), -$5.0 million (Q4 2025), and $5.0 million (Q4 2024), per Business Quant data.